TOP HEADLINES

Featured Story

  • Avita snags $8M from BARDA to aid in PMA filing for ReCell

    Avita Medical will gain an additional $7.96 million to support its plans for U.S. market approval and launch of ReCell. This money, from the Biomedical Advanced Research and Development Authority, supplements the $53.9 million contract that went through last September.

Epic Sciences unveils new, more sensitive biopsy test to detect a range of cancers

San Diego's Epic Sciences has added a new liquid biopsy test to its arsenal of biopharma cancer detection tools that targets homologous recombination deficiencies in individual circulating tumor cells.

MedyMatch, Capital Health to develop artificial intelligence for the emergency room

Stealthy MedyMatch emerged in February with plans to improve emergency room care using cognitive analysis and artificial intelligence. Now, in its first collaboration with a U.S. hospital, the company is developing its first real-time decision-support tool using data from New Jersey-based Capital Health.

Georgetown conducting real-time study of fertility app

Georgetown University's Institute for Reproductive Health is recruiting up to 1,200 women for a real-time study of Cycle Technologies' smartphone app that calculates a woman's fertility on a daily basis.

St. Jude earns CE mark, launches new algorithm for real-time pacemaker adjustment

St. Jude Medical is expanding its cardiac resynchronization therapy portfolio with SyncAV CRT software, which just received CE mark approval. The software builds on the company's MultiPoint Pacing tech.

Nevro rejected by a pair of payers but remains optimistic on reimbursement: Analyst

A pair of regional insurers has decided that treatment using Nevro's Senza neurostimulation device is experimental and will therefore not reimburse it starting next month. Nevro shares dropped 3% in response to the news Wednesday.

MORE NEWS